



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: _____

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/781,263
Filing Date	2/19/2004
First Named Inventor	Yoshiyuki INADA
Art Unit	1626
Examiner Name	Sun Jae Y. LOEWE
Attorney Docket Number	087147-0494

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	E1	Statement of Grounds of Appeal dated January 15, 2008, filed by Strawman Ltd. in Opposition Proceedings of EP 0753301 (31 pgs.).	
	E2	Statement of Grounds of Appeal dated January 21, 2008, filed by Hexal AG in Opposition Proceedings of EP 0753301 (10 pgs.).	
	E3	Response of Takeda Pharmaceutical Company dated July 31, 2008, to statements of Opponents I and II in Opposition Proceedings of EP 0753301 (20 pgs.).	
	E4	DEMERS et al., "Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients with Heart Failure," JAMA, October 12, 2005, 294(14)1794-1798.	
	E5	GRANGER et al., "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial," The Lancet, September 6, 2003, 362:772-776.	
	E6	GRANGER et al., "Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomized, controlled clinical trial," The Lancet, December 10, 2005, 366:2005-2011.	
	E7	INADA et al., "Inhibition of Angiotensin Converting Enzyme by (R)-3-[(S)-1-Carboxy-5-(4- Piperidyl)pentyl]amino-4-Oxo-2,3,4,5-Tetrahydro-1,5-Benzothiazepine-5-Acetic Acid (CV-5975), a Non- Sulphydryl Compound," Japan J. Pharmacol., 1988, 48:323-330.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: _____ <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/781,263
				Filing Date	2/19/2004
				First Named Inventor	Yoshiyuki INADA
				Art Unit	1626
				Examiner Name	Sun Jae Y. LOEWE
				Attorney Docket Number	087147-0494
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	E8	JONG et al., "Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study," The Lancet, May 31, 2003, 361:1843-1848.		
	E9	McKELVIE et al., "Comparison of Candesartan, Analapril, and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study," Circulation 1999, 100:1056-1064.		
	E10	McMURRAY et al., "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial," The Lancet, September 6, 2003, 362:767-771.		
	E11	MIZUNO et al., "Hypotensive Activity of TCV-116, a Newly Developed Angiotensin II Receptor Antagonist, in Spontaneously Hypertensive Rats," Life Sciences, 1992, 51(20):183-187		
	E12	PFEFFER et al., "Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme," The Lancet, September 6, 2003, 362:759-766.		
	E13	URATA et al., "Identification of a Highly Specific Chymase as the Major Angiotensin II-forming Enzyme in the Human Heart," J. Biol. Chem., December 25, 1990, 265(36):22348-22357.		
	E14	VERMA et al., "Angiotensin receptor blockers and myocardial infarction," BMJ, November 27, 2004, 329:1248-1249.		
	E15	WONG et al., "In Vivo Pharmacology of DuP 753," AJH, April 1991, 4(4,2):288S-298S.		
	E16	YUSUF et al., "Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trail," The Lancet, September 6, 2003, 362:777-781.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.